Lyell Immunopharma (NASDAQ:LYEL) Stock Rating Upgraded by Zacks Research

Lyell Immunopharma (NASDAQ:LYEL) was upgraded by analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a research report issued on Monday,Zacks.com reports.

Several other brokerages also recently issued reports on LYEL. Weiss Ratings reissued a “sell (d-)” rating on shares of Lyell Immunopharma in a research report on Tuesday, April 21st. Citizens Jmp started coverage on shares of Lyell Immunopharma in a research report on Monday, March 9th. They set a “market outperform” rating and a $34.00 price objective on the stock. Wall Street Zen raised shares of Lyell Immunopharma from a “sell” rating to a “hold” rating in a research report on Sunday, May 10th. Needham & Company LLC reissued a “buy” rating and set a $44.00 price objective on shares of Lyell Immunopharma in a research report on Thursday, May 7th. Finally, Robert W. Baird set a $49.00 price objective on shares of Lyell Immunopharma and gave the stock an “outperform” rating in a research report on Thursday, April 30th. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $43.00.

Lyell Immunopharma Price Performance

NASDAQ LYEL opened at $16.13 on Monday. The firm’s fifty day moving average price is $21.40 and its 200 day moving average price is $23.58. The company has a market capitalization of $376.31 million, a price-to-earnings ratio of -1.17 and a beta of -0.05. Lyell Immunopharma has a 12 month low of $7.65 and a 12 month high of $45.00.

Lyell Immunopharma (NASDAQ:LYEL) last posted its earnings results on Wednesday, May 6th. The company reported ($1.10) EPS for the quarter, meeting analysts’ consensus estimates of ($1.10). The firm had revenue of $0.00 million for the quarter, compared to the consensus estimate of $0.00 million. Lyell Immunopharma had a negative net margin of 794,858.12% and a negative return on equity of 85.71%. As a group, sell-side analysts forecast that Lyell Immunopharma will post -8.37 earnings per share for the current year.

Institutional Trading of Lyell Immunopharma

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. ARCH Venture Management LLC lifted its stake in shares of Lyell Immunopharma by 51.5% in the third quarter. ARCH Venture Management LLC now owns 2,759,072 shares of the company’s stock valued at $44,807,000 after purchasing an additional 938,438 shares during the period. GSK plc acquired a new stake in shares of Lyell Immunopharma in the fourth quarter valued at about $46,560,000. MWG Caph Ltd acquired a new stake in shares of Lyell Immunopharma in the fourth quarter valued at about $31,030,000. Vanguard Group Inc. lifted its stake in shares of Lyell Immunopharma by 76.0% in the third quarter. Vanguard Group Inc. now owns 779,004 shares of the company’s stock valued at $12,651,000 after purchasing an additional 336,378 shares during the period. Finally, Acadian Asset Management LLC lifted its stake in shares of Lyell Immunopharma by 204.2% in the first quarter. Acadian Asset Management LLC now owns 660,899 shares of the company’s stock valued at $354,000 after purchasing an additional 443,614 shares during the period. Institutional investors and hedge funds own 66.05% of the company’s stock.

About Lyell Immunopharma

Lyell Immunopharma is a clinical-stage biotechnology company focused on developing next-generation T cell therapies for cancer. Leveraging a proprietary platform that combines cell therapy, gene editing and molecular discovery, Lyell seeks to overcome key barriers in the treatment of solid tumors. The company’s approach centers on engineering T cells to enhance their persistence, functionality and resistance to the immunosuppressive tumor microenvironment.

The company’s pipeline includes multiple autologous T cell programs engineered to target tumor-associated antigens in solid malignancies such as melanoma, ovarian and pancreatic cancers.